📊 CPMV Key Takeaways
Is Mosaic ImmunoEngineering Inc. (CPMV) a Good Investment?
Mosaic ImmunoEngineering exhibits severe financial distress with negative stockholders' equity of -$7.3M, liabilities exceeding assets by a substantial margin, and minimal operating capacity. The company is burning cash with negative operating cash flow of -$83.3K, deteriorating liquidity ratios (0.01x current ratio), and lacks meaningful revenue generation, making continued operations unsustainable without significant capital infusion or restructuring.
Fundamentals indicate a highly distressed business with minimal asset coverage, severe liquidity pressure, and deeply negative equity. Although net loss improved modestly year over year and gross profit was positive, the company still appears to lack durable operating scale, strong revenue visibility, and balance-sheet capacity to support sustainable growth.
Why Buy Mosaic ImmunoEngineering Inc. Stock? CPMV Key Strengths
- Minimal capital expenditure requirements suggest low ongoing operational needs
- Small absolute scale of cash burn provides limited time before complete depletion
- Historical data suggests some previous gross profit generation capability
- Net loss and diluted EPS improved modestly year over year
- Positive gross profit suggests some underlying monetization activity
- Free cash flow burn was limited in absolute dollars for the period
CPMV Stock Risks: Mosaic ImmunoEngineering Inc. Investment Risks
- Negative stockholders' equity indicating technical insolvency and potential equity wipeout
- Critical liquidity crisis with current ratio of 0.01x and only $31.8K cash against $7.4M liabilities
- Negative operating cash flow combined with revenue N/A indicates non-viable business model
- Net losses continuing to accumulate with persistent operating deficits
- Zero insider activity in last 90 days suggests management disengagement
- Extremely poor asset efficiency with -938% ROA
- Extreme balance-sheet weakness with negative stockholders' equity of about $7.31 million
- Acute liquidity stress, with only about $31.76 thousand of cash and a 0.01x current ratio
- Very weak growth quality due to unclear revenue base, ongoing operating losses, and negative operating cash flow
Key Metrics to Watch
- Stockholders equity trajectory toward reorganization or dissolution
- Cash burn rate and months of cash runway remaining
- Revenue generation attempts and gross margin sustainability
- Cash balance and operating cash burn
- Revenue generation quality and liability reduction/equity recovery
Mosaic ImmunoEngineering Inc. (CPMV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CPMV Profit Margin, ROE & Profitability Analysis
CPMV vs Healthcare Sector: How Mosaic ImmunoEngineering Inc. Compares
How Mosaic ImmunoEngineering Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Mosaic ImmunoEngineering Inc. Stock Overvalued? CPMV Valuation Analysis 2026
Based on fundamental analysis, Mosaic ImmunoEngineering Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Mosaic ImmunoEngineering Inc. Balance Sheet: CPMV Debt, Cash & Liquidity
CPMV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Mosaic ImmunoEngineering Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.13 indicates the company is currently unprofitable.
CPMV Revenue Growth, EPS Growth & YoY Performance
Mosaic ImmunoEngineering Inc. Dividends, Buybacks & Capital Allocation
CPMV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Mosaic ImmunoEngineering Inc. (CIK: 0000836564)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CPMV
What is the AI rating for CPMV?
Mosaic ImmunoEngineering Inc. (CPMV) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CPMV's key strengths?
Claude: Minimal capital expenditure requirements suggest low ongoing operational needs. Small absolute scale of cash burn provides limited time before complete depletion. ChatGPT: Net loss and diluted EPS improved modestly year over year. Positive gross profit suggests some underlying monetization activity.
What are the risks of investing in CPMV?
Claude: Negative stockholders' equity indicating technical insolvency and potential equity wipeout. Critical liquidity crisis with current ratio of 0.01x and only $31.8K cash against $7.4M liabilities. ChatGPT: Extreme balance-sheet weakness with negative stockholders' equity of about $7.31 million. Acute liquidity stress, with only about $31.76 thousand of cash and a 0.01x current ratio.
What is CPMV's revenue and growth?
Mosaic ImmunoEngineering Inc. reported revenue of N/A.
Does CPMV pay dividends?
Mosaic ImmunoEngineering Inc. does not currently pay dividends.
Where can I find CPMV SEC filings?
Official SEC filings for Mosaic ImmunoEngineering Inc. (CIK: 0000836564) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CPMV's EPS?
Mosaic ImmunoEngineering Inc. has a diluted EPS of $-0.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CPMV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Mosaic ImmunoEngineering Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CPMV stock overvalued or undervalued?
Valuation metrics for CPMV: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CPMV stock in 2026?
Our dual AI analysis gives Mosaic ImmunoEngineering Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CPMV's free cash flow?
Mosaic ImmunoEngineering Inc.'s operating cash flow is $-83.3K, with capital expenditures of $0.0.
How does CPMV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.01 (avg: 2).